Boston Scientific’s Cardiovascular Segment: Q1 2018 Performance
Boston Scientific’s (BSX) Cardiovascular segment is comprised of cardiology and peripheral interventions. Its operating income was $290 million, or 31.1% of the segment’s revenues, in Q1 2018, up from $233 million, or 27.3% of the segment’s revenues, in Q1 2017. Worldwide interventional cardiology sales increased 10%, from $590 million in Q1 2017 to $645 million in Q1 2018.